Pharmaceuticals News and Research

RSS

Contaminated drug passed lab test

Products from the Massachusetts pharmacy linked to the deadly meningitis outbreak passed a lab test in May, reports The Wall Street Journal. In addition, the pharmacy dodged a reprimand by Massachusetts regulators in 2004 after protesting it would be "fatal to the business." The company's founders come under scrutiny by media outlets as more people file lawsuits.

26 Oct 2012

Journal of Pediatrics assesses issues surrounding lack of clinical drug trials for neonates

Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.

26 Oct 2012

Differing opinions about AMFm 'unlikely to be resolved' after Global Fund decision on program's future

In her "Global Health Blog," Guardian health editor Sarah Boseley examines the Affordable Medicines Facility-malaria (AMFm), "which aims to enable countries to increase the provision of affordable artemisinin combination therapies (ACTs) through not only the public sector but also the private sector and [non-governmental organizations (NGOs)]."

26 Oct 2012

NewYork-Presbyterian/Columbia participates in Symplicity system trial for hypertension

Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.

From Medtronic 26 Oct 2012

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic and head & neck cancer.

26 Oct 2012

NAFC conducts online survey to examine women’s perceptions about overactive bladder

The National Association For Continence (NAFC) is conducting an anonymous online survey to understand the perceptions women, age 40-65, have about overactive bladder (OAB) and what they are prepared to do about its symptoms. Using constructs from the Health Belief Model, this survey aims to explain the fears and preparedness women have towards general health and OAB. This research is conducted by Kelton Global Research, a market research company and supported by a grant from Merck Pharmaceuticals.

26 Oct 2012

USPTO issues patent to Tobira’s cenicriviroc for treatment of HIV-1 infection

Tobira Therapeutics, Inc., developer of innovative antiretroviral therapies for HIV, today announced the United States Patent and Trademark Office has issued patent 8,183,273, claiming compositions of matter of a broad family of compounds with activity against chemokine receptors CCR5 and CCR2.

26 Oct 2012

GlaxoSmithKline introduces Complete the Cycle Recycle Program for GSK Respiratory Inhalers

GlaxoSmithKline plc has introduced a new program to help consumers recycle their empty GSK respiratory inhalers and keep waste out of landfills.

25 Oct 2012

Stability of the novel recombinant human albumins Albucult® and Recombumin® demonstrated by light scattering techniques

In a recently published article, researchers from Novozymes Biopharma (Nottingham, UK) and Malvern Panalytical (Malvern Panalytical, UK) describe collaborative work using light scattering techniques to demonstrate the short- and long-term stability of the novel recombinant human albumins Albucult® and Recombumin®.

From Malvern Panalytical 25 Oct 2012

Exploring the New Biopharmaceutical Contract Manufacturing Offering from Olympus

In this interview, News-Medical talks to Peter Gariepy, to find out about the new Contract Manufacturing Offering (CMO) from Olympus Life Science Solutions.

From Evident Corporation - Life Sciences 25 Oct 2012

Meningitis outbreak spreads; Mass. revokes Compounding Center's license

The Massachusetts Board of Pharmacy has permanently revoked the license of the New England Compounding Center, the facility implicated in a nationwide outbreak of fungal meningitis, Gov. Deval Patrick announced Tuesday. ... State Director of Healthcare Safety Madeleine Biondolillo said ... investigators witnessed "black particulate matter" in some vials of medicine returned amid the nationwide recall of NECC's products.

25 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

Scientists unravel physical properties of lung mucus

Mucus coats our airways' internal surfaces. The viscous gel humidifies the lungs and prevents viruses and other small particles like diesel soot from entering the body unchecked. Previously unclear was the extent to which such nanoparticles are able to move through the lungs' mucus. Here, the research evidence was contradictory. Scientists could not explain why, in inhaled medication development, drug nanoparticles often simply got stuck in the mucus never making it to their target destination inside the lung cells.

25 Oct 2012

FDA accepts ARIAD’s ponatinib NDA for filing

ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

25 Oct 2012

DSM extends license to supply CarboSil® TSPCU for use in AxioMed Spine Corporation’s Freedom® Spinal Discs

DSM, a global leader in biomedical materials sciences, and AxioMed Spine Corporation, an innovator in the field of spinal implant devices, today announced that they have revised and extended an existing licensing and supply agreement. DSM will supply its proprietary CarboSil®Thermoplastic Silicone-Polycarbonate-urethane material for use in AxioMed’s Freedom® Lumbar and Freedom® Cervical Discs.

24 Oct 2012

Flu protection: an interview with Dr Gillian SteelFisher of the Harvard School of Public Health in Boston, USA

In 2009, a new strain of influenza, or flu, virus emerged and spread rapidly to many countries around the world. It was declared a pandemic by the World Health Organization (WHO) in June 2009.

24 Oct 2012

Meningitis outbreak linked to pharmaceutical compounding has long history

News outlets report that the FDA released a list of customers - including some major hospitals - of the New England Compounding Center. But the FDA later "found technical problems" and withdrew the list, promising to repost it as soon as the data are corrected.

24 Oct 2012

Bayer announces data from riociguat Phase III trial on CTEPH

Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.

24 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Blood-circulating monocytes can replace brain resident microglia

The immune system is comprised of multiple cell types each capable of specialized functions to protect the body from invading pathogens and promote tissue repair after injury. One cell type, known as monocytes, circulates throughout the organism in the blood and enters tissues to actively phagocytose (eat!) foreign cells and assist in tissue healing.

23 Oct 2012

Pharmaceuticals News and Research

Contaminated drug passed lab test

Journal of Pediatrics assesses issues surrounding lack of clinical drug trials for neonates

Differing opinions about AMFm 'unlikely to be resolved' after Global Fund decision on program's future

NewYork-Presbyterian/Columbia participates in Symplicity system trial for hypertension

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

NAFC conducts online survey to examine women’s perceptions about overactive bladder

USPTO issues patent to Tobira’s cenicriviroc for treatment of HIV-1 infection

GlaxoSmithKline introduces Complete the Cycle Recycle Program for GSK Respiratory Inhalers

Stability of the novel recombinant human albumins Albucult® and Recombumin® demonstrated by light scattering techniques

Exploring the New Biopharmaceutical Contract Manufacturing Offering from Olympus

Meningitis outbreak spreads; Mass. revokes Compounding Center's license

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

Scientists unravel physical properties of lung mucus

FDA accepts ARIAD’s ponatinib NDA for filing

DSM extends license to supply CarboSil® TSPCU for use in AxioMed Spine Corporation’s Freedom® Spinal Discs

Flu protection: an interview with Dr Gillian SteelFisher of the Harvard School of Public Health in Boston, USA

Meningitis outbreak linked to pharmaceutical compounding has long history

Bayer announces data from riociguat Phase III trial on CTEPH

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Blood-circulating monocytes can replace brain resident microglia

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence